MET and neoplasm: However, the levels of VEGFR2 and MET were very low or undetectable in LuCaP 23.1 and C4-2B tumors, and because very little of the tumor tissue was available following cabozantinib treatment, we could not evaluate the on target effects by looking at decreases in phosphorylaiton of these targets.